Alex Stoinescu

Ms. Alex Stoinescu

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
KDKeanna Dube
Keanna Dube
ASAlex Stoinescu
Alex Stoinescu
SPSiyaram Pandey
Siyaram Pandey
Background/Objectives: Neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) represent a growing public health concern. Both disorders are driven by mitochondrial dysfunction, oxidative stress, impaired autophagy, neuroinflammation, and neuronal loss. Single-target therapeutics have failed to halt disease progression, highlighting the need for multi-target interventions that address the complex and interconnected nature of neurodegeneration. Natural health products (NHPs) such as curcumin (CUR), coenzyme-Q10 (CoQ10), and Ashwagandha (ASH) possess antioxidant, anti-inflammatory, neuroprotective, and neurotrophic properties that may collectively address this complex pathology. However, poor bioavailability and hydrophobicity have limited clinical translations. Novel formulations, including nanomicellar Ubisol-Q10 (UQ) and water-solubilized ASH (PTS-ASH), have demonstrated enhanced metabolic uptake and neuroprotective efficacy in preclinical models. Moreover, co-administered NHPs, such as CUR + CoQ10 and CoQ10 + ASH, may provide further benefits by diversified targeting of disease pathways. Methods: This review presents an integrative interpretation of a combined UQ + ASH “tonic” in transgenic AD and paraquat-induced PD animal models using previously published qualitative immunohistochemical and functional results. This report constructs a proposed mechanistic model illustrating how these compounds may interact across multiple stages of disease AD and PD progression. Results: Based on comprehensive interpretation of the previous published reports, consistent trends suggest UQ stabilizes mitochondrial energetics and suppresses oxidative damage upstream, whereas ASH promotes downstream repair and synaptic modulation. Combined administration remained as providing balanced neuroprotective and functional outcomes. Conclusions: These interpretations of published reports and proposed mechanistic models aim to improve the translation and support the therapeutic potential of multi-component natural interventions for neurodegenerative diseases and highlight the importance of bioavailability-enhancing formulations in future preclinical and clinical research.

5 October 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
KDKeanna Dube
Keanna Dube
ASAlex Stoinescu
Alex Stoinescu
JSJulia Sadler
Julia Sadler
MTMichelle Truong
Michelle Truong
NMNatasha Malakoti-Negad
Natasha Malakoti-Negad
SPSiyaram Pandey
Siyaram Pandey
Background/Objectives: Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder characterized by interconnected pathological processes including mitochondrial dysfunction, oxidative stress, impaired autophagic processes, neuroinflammation, neuronal degeneration, and progressive functional decline. Natural health products (NHPs), coenzyme-Q10 (CoQ10) and Ashwagandha (Withania somnifera) (ASH), have been previously reported to possess antioxidant, anti-inflammatory, mitochondrial-supportive, neuroprotective, and neurotrophic properties. This work investigates the neuroprotective effects of a bioavailability-enhanced formulation, Ubisol-Q10 (UQ), and ethanolic ASH extract, combined as a “Tonic,” across multiple domains of AD pathology. Methods: The effects of long-term administration were evaluated in male and female 5XFAD mice from 2.5 to 11 months of age. Longitudinal magnetic resonance imaging assessed hippocampal and white matter volumes, a frailty index assessed physiological resilience, Novel Object and Novel Location Recognition testing assessed spatial and non-spatial memory, while post-mortem Nissl, Golgi–Cox, and immunofluorescence evaluated cellular density, dendritic morphology, amyloid pathology, neuroinflammation, autophagy-associated signaling, and astrocytic activity. Results: Across these measures, Tonic treatment preserved brain volumes, reduced amyloid pathology and inflammation, and modulated autophagy-associated pathways. Treatment also preserved dendritic architecture, frailty progression, and novelty-recognition behavior. Females demonstrated particularly pronounced preservation of white matter structure and increased dendritic density, whereas males showed strong modulation of inflammatory and autophagy-associated markers. Astrocytic immunoreactivity also demonstrated sex- and region-specific patterns, suggesting that glial responses may contribute differently to structural preservation in males and females. Conclusions: Together, these findings support that UQ + ASH may provide diverse protection against AD neurodegeneration. The observed sex-specific responses emphasize the importance of incorporating sex into preclinical evaluation of novel interventions for neurodegenerative diseases.